Home » Newsletters » BioWorld Science

BioWorld Science

July 30, 2007

View Archived Issues

Kissei enters development agreement with Nuon Therapeutics for Rizaben

First milestone investment planned by Amorfix-Biogen Idec partnership

Oswaldo Cruz Foundation and Genzyme form research collaboration

Inovio, NCI and IAVI collaborate to evaluate DNA vaccine delivery technology

Fosalvudine tidoxil monotherapy is safe and effective in treatment-naive HIV-infected patients

Maraviroc+optimized antiretroviral background therapy safe and effective:MOTIVATE 1 and 2 trials

Advanced Magnetics changes to AMAG Pharmaceuticals

ChemoCentryx earns milestone payment from GlaxoSmithKline

Favorable profile emerges for second-generation HIV-1 maturation inhibitor from Panacos

Update on Biopure's phase II study of Hemopure

CHMP grants positive opinion of expanded label of Cubicin

GMI-1070: GlycoMimetics' lead pan-selectin antagonist drug candidate for sickle cell crisis

First characterization of a selective nonpeptide formyl peptide receptor-like 1 antagonist

Siemens to acquire Dade Behring

ZARS begins phase III trial of ThermoProfen for osteoarthritis

CytoDyn reports results of DNA vaccine effectiveness comparative study

Tranzyme begins phase IIb trial of TZP-101 for management of POI

Kuvan receives priority review status from FDA

Novel agents for the treatment of endocrine disorders

Gruenenthal presents analgesic agents targeting monoamine uptake and mu receptors

New antiinfectives disclosed in patent literature

Merck to acquire NovaCardia to boost clinical pipeline of cardiovascular drug candidates

Athersys begins phase I trial for ATHX-105 for treatment of obesity

Patient treatment begins in phase I/II trial of MDV-3100 in hormone-refractory prostate cancer

Vyvanse now available in the U.S, for ADHD

EMEA grants orphan drug status to Active Biotech's cancer treatment Anyara

OctoPlus obtains full rights to PolyActive drug delivery technology from IsoTis

Eszopiclone filed for approval in EU and licensed to Eisai in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...